LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

5.41 -19.97

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.4

Max

6.8

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	16.767 61.417
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+70.37% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	204M 852M
Iepriekšējā atvēršanas cena	25.38
Iepriekšējā slēgšanas cena	5.41

Ziņu noskaņojums

By Acuity

38%

62%

105 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. marts 21:37 UTC

Iegādes, apvienošanās, pārņemšana

Lensar and Alcon Agree to Terminate Merger

2026. g. 16. marts 19:06 UTC

Galvenie ziņu notikumi

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

2026. g. 16. marts 17:44 UTC

Iegādes, apvienošanās, pārņemšana

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

2026. g. 16. marts 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 16. marts 23:46 UTC

Tirgus saruna

Nikkei May Rise After Oil Prices Decline -- Market Talk

2026. g. 16. marts 23:37 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 16. marts 23:05 UTC

Tirgus saruna

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

2026. g. 16. marts 21:56 UTC

Tirgus saruna

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

2026. g. 16. marts 21:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 16. marts 21:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

2026. g. 16. marts 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

2026. g. 16. marts 20:51 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. marts 19:53 UTC

Galvenie ziņu notikumi

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

2026. g. 16. marts 19:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 16. marts 19:43 UTC

Tirgus saruna

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

2026. g. 16. marts 19:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Natural Gas Follows Oil Prices Lower -- Market Talk

2026. g. 16. marts 19:20 UTC

Galvenie ziņu notikumi

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

2026. g. 16. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

2026. g. 16. marts 19:00 UTC

Tirgus saruna

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

2026. g. 16. marts 18:23 UTC

Tirgus saruna

LME Restarts Trading After Outage -- Market Talk

2026. g. 16. marts 17:36 UTC

Galvenie ziņu notikumi

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

2026. g. 16. marts 17:19 UTC

Tirgus saruna

Grains Sink as Investors Steer Toward Equities -- Market Talk

2026. g. 16. marts 17:14 UTC

Galvenie ziņu notikumi

Trump Ends News Conference

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

70.37% augšup

Prognoze 12 mēnešiem

Vidējais 11.5 USD 70.37%

Augstākais 17 USD

Zemākais 10 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

105 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.